Exelixis, Inc. (NASDAQ:EXEL) To Cut 160 Jobs After failure of Prostate Cancer Trial

Boston, MA 09/03/2014 (wallstreetpr) – According to recent reports, Exelixis, Inc. (NASDAQ:EXEL) has decided to slash around 160 jobs due to failure of protest cancer trial. The stock prices of EXEL hit all time low after it announced that its drug Cometriq failed at a later stage. The company was trying to find a solution […]